RU2007133287A - Antipopsoriatic agent and method of its use (options) - Google Patents

Antipopsoriatic agent and method of its use (options) Download PDF

Info

Publication number
RU2007133287A
RU2007133287A RU2007133287/15A RU2007133287A RU2007133287A RU 2007133287 A RU2007133287 A RU 2007133287A RU 2007133287/15 A RU2007133287/15 A RU 2007133287/15A RU 2007133287 A RU2007133287 A RU 2007133287A RU 2007133287 A RU2007133287 A RU 2007133287A
Authority
RU
Russia
Prior art keywords
vip
phe
lys
arg
acetyl
Prior art date
Application number
RU2007133287/15A
Other languages
Russian (ru)
Original Assignee
Ионов Иль Давидович (RU)
Ионов Илья Давидович
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ионов Иль Давидович (RU), Ионов Илья Давидович filed Critical Ионов Иль Давидович (RU)
Priority to RU2007133287/15A priority Critical patent/RU2007133287A/en
Publication of RU2007133287A publication Critical patent/RU2007133287A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/25Growth hormone-releasing factor [GH-RF] (Somatoliberin)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/2278Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)

Claims (3)

1. A medication for the treatment of psoriasis, applied by local application to the affected skin, characterized in that it contains at least one antagonist of a vasoactive intestinal (poly) peptide in an effective concentration and one or more pharmaceutically acceptable excipients and carriers.
2. The drug according to claim 1, characterized in that the antagonist of the vasoactive intestinal (poly) peptide is selected from the group including
VIP (6-28);
VIP (10-28);
[Lys (1), Pro (2.5), Arg (3.4), Tyr (6)] - VIP;
[D-p-Cl-Phe (6), Len (17)] - VIP;
[Acetyl-His (1), D-Phe (2), Lys (15), Arg (16), Leu (27)] - VIP (1-7) / GRF (8-27) -NH 2 ;
[Myristoyl-His (1), Lys (12,27,28), Gly (29,30), Thr (31)] VIP-NH 2 ;
[Acetyl-His (1), D-Phe (2), Lys (15), Arg (16), Leu (17)] - VIP;
neurotensin (6-11) VIP (7-28);
[Acetyl-His (1), D-Phe (2), Phe (4-Cl) (6), Har (9), Tyr (Me) (10), Abu (15), Nle (27), D- Arg (28), Har (29)] GRF (1-29) -NH 2 ;
[Acetyl-His (1), D-Phe (2), Phe (4-Cl) (6), Lys (15), Arg (16), Lys (20), Tyr (22), Nle (27), D-Arg (28), Har (29)] GRF (1-29) -NH 2 ;
[Acetyl-His (1), D-Phe (2), Lys (15), Leu (17)] VIP (3-7) / GRF (8-27);
[Acetyl-His (1), D-Phe (2), Lys (15), Arg (16)] VIP (3-7) / GHF (8-27) -NH 2 ;
[Acetyl-Tyr (1), D-Phe (2)] - GRF (1-29) -NH 2 ;
[N-stearyl, norleucine 17] VIP hybrid;
Leu-Met-Tyr-Pro-Thr-Tyr-Leu-Lys;
P-Phe2 [VIP;
PACAP (6-27);
PACAP (6-38).
3. Use of antagonists of a vasoactive intestinal (poly) peptide from the group
VIP (6-28);
VIP (10-28);
[Lys (1), Pro (2.5), Arg (3.4), Tyr (6)] - VIP;
[D-p-Cl-Phe (6), Leu (17)] - VIP;
[Acetyl-His (1), D-Phe (2), Lys (15), Arg (16), Leu (27)] - VIP (1-7) / GRE (8-27) -NH 2 ;
[Myristoyl-His (1), Lys (12,27,28), Gly (29,30), Thr (31)] VIP-NH 2 ;
[Acetyl-His (1), D-Phe (2), Lys (15), Arg (16), Leu (17)] - VIP;
neurotensin (6-11) VIP (7-28);
[Acetyl-His (1), D-Phe (2), Phe (4-Cl) (6), Har (9), Tyr (Me) (10), Abu (15), Nle (27), D- Arg (28), Har (29) GRF (1-29) -NH 2 ;
[Acetyl-His (1), D-Phe (2), Phe (4-Cl) (6), Lys (15), Arg (16), Lys (20), Tyr (22), Nle (27), D-Arg (28), Har (29) GRF (1-29) -NH 2 ;
| Acetyl-His (1), D-Phe (2), Lys (15), Leu (17)] VIP (3-7) / GRF (8-27);
[Acetyl-His (1), D-Phe (2), Lys (15), Arg (16)] VIP (3-7) / GHF (8-27) -NH 2 ;
[Acetyl-Tyr (1), D-Phe (2)] - GRF (1-29) NH 2 ;
[N-steatyl, norleucine 17] VIPhybrid;
Leu-Met-Tyr-Pro-Thr-Tyr-Leu-Lys;
[D-Phe2 [VIP;
PACAP (6-27);
PACAP (6-38).
for the manufacture of an anti-psoriatic drug intended for local use.
RU2007133287/15A 2007-09-05 2007-09-05 Antipopsoriatic agent and method of its use (options) RU2007133287A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU2007133287/15A RU2007133287A (en) 2007-09-05 2007-09-05 Antipopsoriatic agent and method of its use (options)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2007133287/15A RU2007133287A (en) 2007-09-05 2007-09-05 Antipopsoriatic agent and method of its use (options)
PCT/RU2008/000043 WO2009031916A1 (en) 2007-09-05 2008-01-28 Vip antagonists in the form of an agent for treating psoriasis

Publications (1)

Publication Number Publication Date
RU2007133287A true RU2007133287A (en) 2009-03-10

Family

ID=40429092

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2007133287/15A RU2007133287A (en) 2007-09-05 2007-09-05 Antipopsoriatic agent and method of its use (options)

Country Status (2)

Country Link
RU (1) RU2007133287A (en)
WO (1) WO2009031916A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5631201B2 (en) 2007-03-28 2014-11-26 プレジデント アンド フェローズ オブ ハーバード カレッジ Stitched polypeptide
US20110229423A1 (en) * 2008-07-18 2011-09-22 Galderma Research & Development Pacap signaling pathway modulators for treating inflammatory skin diseases having a neurogenic component, notably rosacea, and compositions comprised thereof
RU2582678C2 (en) 2010-08-13 2016-04-27 Эйлерон Терапьютикс, Инк. Peptidomimetic macrocycles
US9096684B2 (en) 2011-10-18 2015-08-04 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
EP2819688A4 (en) 2012-02-15 2015-10-28 Aileron Therapeutics Inc Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
US8927500B2 (en) 2012-02-15 2015-01-06 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US9604919B2 (en) 2012-11-01 2017-03-28 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
US10471120B2 (en) 2014-09-24 2019-11-12 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
AU2016235424A1 (en) 2015-03-20 2017-10-05 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5529983A (en) * 1986-06-03 1996-06-25 The United States Of America As Represented By The Department Of Health And Human Services Use of small peptides in the treatment of psoriasis

Also Published As

Publication number Publication date
WO2009031916A1 (en) 2009-03-12

Similar Documents

Publication Publication Date Title
DK1924577T3 (en) Substituted benzimidazoles and methods of preparation
DK2049165T3 (en) Quick acting dry sealant and methods of use and manufacture
DK2205169T3 (en) Device and method of conveyance
AT537209T (en) Blaster compositions of hydrofluorolefinen and hydrochlorofluorolefinen
DK2222675T3 (en) 5-anilinoimidazopyridines and procedures for their use
DK2234985T3 (en) 4- (4-cyano-2-thioaryl) dihydropyrimidinones and their use
DE602007006835D1 (en) Substituted pyridone compounds and application methods
GB0700919D0 (en) Degradable compositions, apparatus comprising same, and methods of use
BRPI0807225A2 (en) Endio-surgical device and method
DE602007010379D1 (en) Coating composition for medical devices and medical device
EP2379561A4 (en) Mlk inhibitors and methods of use
BRPI0819956A2 (en) Methods and apparatus of new cellular selection.
EP2373163A4 (en) Heterocyclic compounds and methods of use
IL197185D0 (en) Substituted acylanilides and methods of use thereof
PL2038252T3 (en) Substituted acylanilides and methods of use thereof
EP2268351A4 (en) Occlusion device and method of use
AT551334T (en) Pi3-kinase inhibitors and method for their use
EP2091588A4 (en) Cardiac device and methods of use thereof
PL2132987T3 (en) Nematicidal agent composition and method of using the same
BRPI0717638A2 (en) Anticorpors and immunocused and uses for them
BRPI0820457A2 (en) Rupture fluids and methods of use
BRPI0817879A2 (en) Compositions and methods of use of sclerostine antibodies
BRPI0720124A2 (en) Pharmaceutical compositions and methods of use.
ZA201001051B (en) Benzylbenzene derivatives and methods of use
IL198397D0 (en) Anilinopiperazine derivatives and methods of use thereof

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20100906